{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-006233","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.564653+00:00","generated_at":"2026-06-02T00:58:05.153509+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ENDRA Life Sciences reports Q1 net loss of $2.8M; advances TAEUS liver system with FDA and UK clinical study","bullets":["Net loss of $2.8M ($0.26 per share) vs $2.9M ($0.93 per share) in Q1 2023; operating expenses $2.8M.","Cash and cash equivalents were $1.1M as of March 31, 2024.","First TAEUS system installed at King's College Hospital (UK) for a clinical study evaluating liver fat vs MRI (approx 75 subjects).","FDA pre-submission meeting scheduled in Q2 2024 to align on clinical requirements for De Novo application.","Expanded IP portfolio to 80 issued patents globally; exploring licensing for non-core indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-006233","json":"https://secwatch.observer/filing/0001654954-24-006233.json","markdown":"https://secwatch.observer/filing/0001654954-24-006233.md","text":"https://secwatch.observer/filing/0001654954-24-006233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424006233/0001654954-24-006233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424006233/ndra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:58:05.153509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e70f70e5014799b3797e2e164da5ba0ce8a7d021","claim":"ENDRA Life Sciences Inc. reported the three months ended March 31, 2024 results: net income $2.8 million, or $0.26 per share, EPS $0.26 per share.","evidence_excerpt":"Net loss in the first quarter of 2024 was $2.8 million, or $0.26 per share, compared with a net loss of $2.9 million, or $0.93 per share, in the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424006233/0001654954-24-006233-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Net income","value":"$2.8 million, or $0.26 per share"},{"label":"EPS","value":"$0.26 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}